Cartesian Therapeutics (RNAC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Surrozen (SRZN) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 72.6% versus a loss of 30.4%. Over five years, SRZN leads with a -76.7% price change compared with -94.7% for RNAC. Surrozen is the larger company by market cap ($275.5 million vs $189.7 million), about 1.5 times the size.
Cartesian Therapeutics converts more of its revenue into profit, with a net margin of -4658.6% versus -6960.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAC | SRZN |
|---|---|---|
| Share price | $6.27 | $23.44 |
| Market cap | $189.70M | $275.50M |
| 1-day change | -4.71% | -6.50% |
| YTD return | -13.04% | +3.72% |
| 1-year return | -30.41% | +72.61% |
| 5-year return | -94.71% | -76.75% |
| EPS (TTM) | $-5.78 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $3.48M |
| Revenue growth (YoY) | -92.81% | -67.37% |
| Net income (latest FY) | $-130.30M | $-242.03M |
| Operating margin | -5127.10% | -1210.58% |
| Net margin | -4658.63% | -6960.77% |
| 52-week high | $11.00 | $37.83 |
| 52-week low | $5.60 | $11.39 |
| Distance from 52-week high | -43.00% | -38.04% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +437.00% | +106.48% |
| Average volume | 131.23K | 534.47K |
| Shares outstanding | 30.26M | 11.75M |
| Employees | 75 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed RNAC by 103.0 percentage points over the past year.
- Cartesian Therapeutics is more profitable, keeping -4658.6 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
- Surrozen grew revenue faster in its latest fiscal year (-67.37% vs -92.81%).
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Healthcare · Biotechnology · 75 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
RNAC vs SRZN FAQ
Which is bigger, Cartesian Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $275.50M compared with $189.70M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, RNAC or SRZN?
SRZN returned +72.61% over the past 12 months, compared with -30.41% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Cartesian Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.